Category: Multiple myeloma

       In fact, this issue is a cliché, and I have already mentioned it in the “FAQ on multiple myeloma” to patients and their families.　　I would like to…

　　Patients with multiple myeloma enter maintenance therapy after induction chemotherapy and autologous bone marrow transplantation, and maintenance therapy drugs can be selected according to the patient’s condition. Thalidomide (Response Stop)…

　　How long a patient with multiple myeloma can live depends on the patient’s own condition, treatment and the stage of the disease, and the survival period varies from patient to…

　　Multiple myeloma is a primary systemic bone marrow tumor, also known as plasmacytoma, which is a malignant tumor arising from plasma cells. It can occur in any bone containing red…

“The following is a summary of the questions frequently asked by patients and their families, and represents only my personal view.　　I. About the diagnosis of multiple myeloma For the diagnosis…

The treatment of multiple myeloma is mainly based on chemotherapy, which is the common treatment for multiple myeloma. Chemotherapy includes single-agent chemotherapy and combination chemotherapy. Single-agent chemotherapy can be treated…

　　Multiple myeloma is a common tumor of the hematological system. Clinically, it mostly presents with bone destruction and bone pain as the first manifestation, often with bone lesions, and even…

　　What are the common clinical manifestations of multiple myeloma?　　Multiple myeloma can be asymptomatic in the early stage, only by chance to find the increase of blood sedimentation and abnormal immunoglobulin…

　　1. Proteasome inhibitors: Bortezomib has been widely used clinically as a first-generation proteasome inhibitor. Carfilzomib, a second-generation proteasome inhibitor, was approved by the US FDA on July 20, 2012 for…

Most patients with multiple myeloma will show low hemoglobin, or anemia, on their blood work. This type of anemia is moderate, with a hemoglobin value between 60-90 g/L on the…